Astellas Pharma Inc., Japan�"s second- biggest drugmaker, may stem a revenue drop caused by dwindling demand for its top-selling drugs with the planned $4 billion purchase of OSI Pharmaceuticals Inc., Nomura Holdings Inc. said....
Read More...
[Source: BusinessWeek.com -- ]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment